{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:36:18Z","timestamp":1794036978348,"version":"4.8.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["Grant No. LQ24H030008"],"award-info":[{"award-number":["Grant No. LQ24H030008"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cholangiocarcinoma (CCA) is a highly heterogeneous disease with a poor prognosis and a 5-year survival rate of less than 20% due to late diagnosis and limited therapeutic options, and the current problems in the treatment of CCA can be mainly attributed to the low rate of early diagnosis, the limited availability of targeted drugs, and the gradual increase in chemoresistance. Metabolic reprogramming in CCA causes the accumulation of large amounts of lactic acid and glycolytic intermediates, exacerbating hypoxia and the formation of an acidic environment at the tumor site, which further reduces the effectiveness of therapeutic drugs. Amino acid metabolic reprogramming promotes the proliferation, metastasis, spreading, and tumor angiogenesis of CCA cells, and some amino acid metabolites, in turn, regulate the metabolic state and gene expression of cells, which in turn regulates the cellular phenotype. Abnormal metabolism of amino acids negatively affects the progression of CCA. In the amino acid metabolism of CCA, the PI3K\/AKT\/mTOR and AMPK\/Nrf2 pathways are two key pathways, and c-Myc plays an important role in glutamine metabolism as a transcription factor. Future studies should design targeted drugs around the abnormal accumulation process of glutamine, arginine and other amino acids to disrupt the amino acid uptake dominance in malignant tumors, as well as design novel drugs according to the changes in the tumor microenvironment.<\/jats:p>","DOI":"10.1038\/s41420-025-02843-9","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:43:08Z","timestamp":1767969788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Amino acid metabolic reprogramming: future prospects for cholangiocarcinoma therapy"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0563-1065","authenticated-orcid":false,"given":"Sijia","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0913-0501","authenticated-orcid":false,"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiulin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2843_CR1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","volume":"60","author":"J Bridgewater","year":"2014","unstructured":"Bridgewater J, Galle PR, Khan SA, Llovet JM, Park J-W, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268\u201389.","journal-title":"J Hepatol"},{"key":"2843_CR2","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1002\/cncr.30074","volume":"122","author":"JA Flemming","year":"2016","unstructured":"Flemming JA, Zhang-Salomons J, Nanji S, Booth CM. Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: a population-based study. Cancer. 2016;122:2534\u201343.","journal-title":"Cancer"},{"key":"2843_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hepr.13438","volume":"50","author":"M Kudo","year":"2020","unstructured":"Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50:15\u201346.","journal-title":"Hepatol Res"},{"key":"2843_CR4","doi-asserted-by":"crossref","unstructured":"Kubo S, Shinkawa,H Asaoka Y, Ioka T, Igaki H, Izumi, N, et al. Liver cancer study group of Japan clinical practice guidelines fot intrahepatic cholangiocarcinoma. Liver Cancer. 2022;11:290\u2013314.","DOI":"10.1159\/000522403"},{"key":"2843_CR5","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","volume":"84","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936.","journal-title":"Cancer Treat Rev."},{"key":"2843_CR6","first-page":"198","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73:198\u2013222.","journal-title":"CA Cancer J Clin"},{"key":"2843_CR7","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.3390\/cancers14092137","volume":"14","author":"E Woods","year":"2022","unstructured":"Woods E, Le D, Jakka BK, Manne A. Changing landscape of systemic therapy in biliary tract cancer. Cancers. 2022;14:2137.","journal-title":"Cancers"},{"key":"2843_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1097\/JS9.0000000000002013","volume":"111","author":"Z Zheng","year":"2025","unstructured":"Zheng Z, Wang J, Wu T, He M, Pan Y, Wang J, et al. Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a retrospective cohort study. Int J Surg. 2025;111:1552\u20137.","journal-title":"Int J Surg"},{"key":"2843_CR9","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1038\/onc.2012.617","volume":"32","author":"D Sia","year":"2013","unstructured":"Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013;32:4861\u201370.","journal-title":"Oncogene"},{"key":"2843_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","volume":"22","author":"A Moeini","year":"2016","unstructured":"Moeini A, Sia D, Bardeesy N, Mazzaferro V, Llovet JM. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016;22:291\u2013300.","journal-title":"Clin Cancer Res"},{"key":"2843_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli MP, Janes MR, Li L-S, Hansen R, Peters U, Kessler LV, et al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov. 2016;6:316\u201329.","journal-title":"Cancer Discov."},{"key":"2843_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","volume":"3","author":"A Pellino","year":"2018","unstructured":"Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol. 2018;3:40.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"2843_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/0008-5472.CAN-24-1173","volume":"85","author":"J Nie","year":"2025","unstructured":"Nie J, Zhang S, Guo Y, Liu C, Shi J, Wu H, et al. Mapping of the T-cell landscape of biliary tract cancer unravels anatomic subtype-specific heterogeneity. Cancer Res. 2025;85:704\u201322.","journal-title":"Cancer Res"},{"key":"2843_CR14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jhep.2024.02.008","volume":"80","author":"JL Tomlinson","year":"2024","unstructured":"Tomlinson JL, Li B, Yang J, Loeuillard E, Stumpf HE, Kuipers H, et al. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma. J Hepatol. 2024;80:892\u2013903.","journal-title":"J Hepatol."},{"key":"2843_CR15","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1016\/j.ymthe.2024.06.006","volume":"32","author":"P Gondaliya","year":"2024","unstructured":"Gondaliya P, Sayyed AA, Yan IK, Driscoll J, Ziemer A, Patel T. Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy. Mol Ther. 2024;32:2762\u201377.","journal-title":"Mol Ther."},{"key":"2843_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000534443","volume":"13","author":"N Nishida","year":"2024","unstructured":"Nishida N, Kudo M. Genetic\/epigenetic alteration and tumor immune microenvironment in intrahepatic cholangiocarcinoma: transforming the immune microenvironment with molecular-targeted agents. Liver Cancer. 2024;13:136\u201349.","journal-title":"Liver Cancer"},{"key":"2843_CR17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","volume":"77","author":"C Raggi","year":"2022","unstructured":"Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77:849\u201364.","journal-title":"J Hepatol"},{"key":"2843_CR18","doi-asserted-by":"publisher","first-page":"217714","DOI":"10.1016\/j.canlet.2025.217714","volume":"622","author":"Q Wang","year":"2025","unstructured":"Wang Q, Long T, Tang P, Xu C, Wang L, Liu J. Metabolic reprogramming in cholangiocarcinoma cancer stem cells: emerging therapeutic paradigms. Cancer Lett. 2025;622:217714.","journal-title":"Cancer Lett"},{"key":"2843_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","volume":"14","author":"UE Martinez-Outschoorn","year":"2017","unstructured":"Martinez-Outschoorn UE, Peiris-Pag\u00e9s M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14:11\u201331.","journal-title":"Nat Rev Clin Oncol"},{"key":"2843_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/metabo11010028","volume":"11","author":"K Ohshima","year":"2021","unstructured":"Ohshima K, Morii E. Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabolites. 2021;11:28.","journal-title":"Metabolites"},{"key":"2843_CR21","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200.","journal-title":"Sci Adv"},{"key":"2843_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41420-025-02351-w","volume":"11","author":"J Zhang","year":"2025","unstructured":"Zhang J, Ruan K, Chu Z, Wang X, Gu Y, Jin H, et al. Reprogramming of fatty acid metabolism: a hidden force regulating the occurrence and progression of cholangiocarcinoma. Cell Death Discov. 2025;11:72.","journal-title":"Cell Death Discov"},{"key":"2843_CR23","doi-asserted-by":"crossref","unstructured":"Unterlass JE, Curtin NJ, Warburg and Krebs and related effects in cancer. 2019;21:e4.","DOI":"10.1017\/erm.2019.4"},{"key":"2843_CR24","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","volume":"95","author":"P Vaupel","year":"2019","unstructured":"Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019;95:912\u20139.","journal-title":"Int J Radiat Biol"},{"key":"2843_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the Intersections between Metabolism and Cancer Biology. Cell. 2017;168:657\u201369.","journal-title":"Cell"},{"key":"2843_CR26","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/ijms19113466","volume":"19","author":"CW Yun","year":"2018","unstructured":"Yun CW, Lee SH. The roles of autophagy in cancer. Int J Mol Sci. 2018;19:3466.","journal-title":"Int J Mol Sci"},{"key":"2843_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","volume":"35","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Yu T-J, Xu Y, Ding R, Wang Y-P, Jiang Y-Z, et al. Emerging therapies in cancer metabolism. Cell Metab. 2023;35:1283\u2013303.","journal-title":"Cell Metab"},{"key":"2843_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21:141\u201362.","journal-title":"Nat Rev Drug Discov"},{"key":"2843_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.tem.2021.03.003","volume":"32","author":"M Butler","year":"2021","unstructured":"Butler M, van der Meer LT, van Leeuwen FN. Amino acid depletion therapies: starving cancer cells to death. Trends Endocrinol Metab. 2021;32:367\u201381.","journal-title":"Trends Endocrinol Metab"},{"key":"2843_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neo.2019.10.004","volume":"22","author":"J Wappler","year":"2020","unstructured":"Wappler J, Arts M, R\u00f6th A, Heeren RMA, Peter Neumann U, Olde Damink SW, et al. Glutamine deprivation counteracts hypoxia-induced chemoresistance. Neoplasia. 2020;22:22\u201332.","journal-title":"Neoplasia"},{"key":"2843_CR31","doi-asserted-by":"publisher","first-page":"167152","DOI":"10.1016\/j.bbadis.2024.167152","volume":"1870","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Zhou J, Zhai D, Jiang Q, Yang M, Zhou M. Gut microbiota regulates the ALK5\/NOX1 axis by altering glutamine metabolism to inhibit ferroptosis of intrahepatic cholangiocarcinoma cells. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167152.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2843_CR32","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1097\/CM9.0000000000002380","volume":"136","author":"M Shao","year":"2023","unstructured":"Shao M, Tao Q, Xu Y, Xu Q, Shu Y, Chen Y, et al. Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy. Chin Med J. 2023;136:2066\u201376.","journal-title":"Chin Med J."},{"key":"2843_CR33","doi-asserted-by":"publisher","first-page":"22830","DOI":"10.3390\/ijms160922830","volume":"16","author":"L Chen","year":"2015","unstructured":"Chen L, Cui H. Targeting glutamine induces apoptosis: a cancer therapy approach. Int J Mol Sci. 2015;16:22830\u201355.","journal-title":"Int J Mol Sci"},{"key":"2843_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.5483\/BMBRep.2023-0029","volume":"56","author":"SM Yang","year":"2023","unstructured":"Yang SM, Kim J, Lee JY, Lee JS, Lee JM. Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma. BMB Rep. 2023;56:600\u20135.","journal-title":"BMB Rep"},{"key":"2843_CR35","doi-asserted-by":"publisher","first-page":"101643","DOI":"10.1016\/j.redox.2020.101643","volume":"36","author":"H Endo","year":"2020","unstructured":"Endo H, Owada S, Inagaki Y, Shida Y, Tatemichi M. Metabolic reprogramming sustains cancer cell survival following extracellular matrix detachment. Redox Biol. 2020;36:101643.","journal-title":"Redox Biol"},{"key":"2843_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13046-025-03400-z","volume":"44","author":"Y Gong","year":"2025","unstructured":"Gong Y, Chen L, Wang H, Zheng D, Li F, Wu C, et al. ANXA1 promotes intrahepatic cholangiocarcinoma proliferation and growth by regulating glutamine metabolism through GOT1 stabilization. J Exp Clin Cancer Res. 2025;44:151.","journal-title":"J Exp Clin Cancer Res"},{"key":"2843_CR37","doi-asserted-by":"crossref","unstructured":"Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov.2015;5:1024\u201339.","DOI":"10.1158\/2159-8290.CD-15-0507"},{"key":"2843_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2006.07.014","volume":"16","author":"CV Dang","year":"2006","unstructured":"Dang CV, O\u2019Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253\u201364.","journal-title":"Semin Cancer Biol"},{"key":"2843_CR39","doi-asserted-by":"publisher","first-page":"a014217","DOI":"10.1101\/cshperspect.a014217","volume":"3","author":"CV Dang","year":"2013","unstructured":"Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med. 2013;3:a014217.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2843_CR40","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/hep.28607","volume":"64","author":"C Berasain","year":"2016","unstructured":"Berasain C, Fern\u00e1ndez-Barrena MG, Avila MA. New molecular interactions of c-Myc in cholangiocarcinoma may open new therapeutic opportunities. Hepatology. 2016;64:336\u20139.","journal-title":"Hepatology"},{"key":"2843_CR41","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K, Ochi T, et al. c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762\u20135.","journal-title":"Nature"},{"key":"2843_CR42","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/hep.28781","volume":"64","author":"J Wang","year":"2016","unstructured":"Wang J, Xie C, Pan S, Liang Y, Han J, Lan Y, et al. N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor\/MicroRNA-181c negative feedback pathway. Hepatology. 2016;64:1606\u201322.","journal-title":"Hepatology"},{"key":"2843_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep36138","volume":"6","author":"K-C Chiang","year":"2016","unstructured":"Chiang K-C, Yeh T-S, Wu R-C, Pang J-HS, Cheng C-T, Wang S-Y, et al. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker. Sci Rep. 2016;6:36138.","journal-title":"Sci Rep"},{"key":"2843_CR44","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.7150\/ijbs.48066","volume":"16","author":"M Ding","year":"2020","unstructured":"Ding M, Bu X, Li Z, Xu H, Feng L, Hu J, et al. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2. Int J Biol Sci. 2020;16:3100\u201315.","journal-title":"Int J Biol Sci"},{"key":"2843_CR45","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.3748\/wjg.v25.i31.4300","volume":"25","author":"B Murray","year":"2019","unstructured":"Murray B, Barbier-Torres L, Fan W, Mato JM, Lu SC. Methionine adenosyltransferases in liver cancer. World J Gastroenterol. 2019;25:4300\u201319.","journal-title":"World J Gastroenterol"},{"key":"2843_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/hep.28541","volume":"64","author":"H Yang","year":"2016","unstructured":"Yang H, Liu T, Wang J, Li TWH, Fan W, Peng H, et al. Deregulated methionine adenosyltransferase \u03b11, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans(\u2021). Hepatology. 2016;64:439\u201355.","journal-title":"Hepatology"},{"key":"2843_CR47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0168-8278(00)80122-1","volume":"33","author":"MA Avila","year":"2000","unstructured":"Avila MA, Berasain C, Torres L, Mart\u00edn-Duce A, Corrales FJ, Yang H, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol. 2000;33:907\u201314.","journal-title":"J Hepatol"},{"key":"2843_CR48","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s13046-022-02549-1","volume":"41","author":"C Gao","year":"2022","unstructured":"Gao C, Zhou G, Shi J, Shi P, Jin L, Li Y, et al. The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF-\u03baB1 p105 to p50. J Exp Clin Cancer Res. 2022;41:338.","journal-title":"J Exp Clin Cancer Res"},{"key":"2843_CR49","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13287-022-02988-9","volume":"13","author":"L Huang","year":"2022","unstructured":"Huang L, Xu D, Qian Y, Zhang X, Guo H, Sha M, et al. A gene signature is critical for intrahepatic cholangiocarcinoma stem cell self-renewal and chemotherapeutic response. Stem Cell Res Ther. 2022;13:292.","journal-title":"Stem Cell Res Ther"},{"key":"2843_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00415-5","volume":"11","author":"S Lu","year":"2022","unstructured":"Lu S, Ke S, Wang C, Xu Y, Li Z, Song K, et al. NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis. Oncogenesis. 2022;11:39.","journal-title":"Oncogenesis"},{"key":"2843_CR51","first-page":"155","volume":"13","author":"S Kidoikhammouan","year":"2012","unstructured":"Kidoikhammouan S, Seubwai W, Tantapotinan N, Silsirivanit A, Wongkham S, Sawanyawisuth K, et al. TNP-470, a methionine aminopeptidase-2 inhibitor, inhibits cell proliferation, migration and invasion of human cholangiocarcinoma cells in vitro. Asian Pac J Cancer Prev. 2012;13:155\u201360.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2843_CR52","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/hep.25643","volume":"56","author":"M Frau","year":"2012","unstructured":"Frau M, Tomasi ML, Simile MM, Demartis MI, Salis F, Latte G, et al. Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology. 2012;56:165\u201375.","journal-title":"Hepatology"},{"key":"2843_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1053\/j.gastro.2018.04.032","volume":"155","author":"T Liu","year":"2018","unstructured":"Liu T, Yang H, Fan W, Tu J, Li TWH, Wang J, et al. Mechanisms of MAFG dysregulation in cholestatic liver injury and development of liver cancer. Gastroenterology. 2018;155:557\u201371.e14.","journal-title":"Gastroenterology"},{"key":"2843_CR54","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1038\/s41388-021-01980-6","volume":"40","author":"L Lu","year":"2021","unstructured":"Lu L, Zhang J, Fan W, Li Y, Wang J, Li TWH, et al. Deregulated 14-3-3\u03b6 and methionine adenosyltransferase \u03b11 interplay promotes liver cancer tumorigenesis in mice and humans. Oncogene. 2021;40:5866\u201379.","journal-title":"Oncogene"},{"key":"2843_CR55","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13046-022-02386-2","volume":"41","author":"L Colyn","year":"2022","unstructured":"Colyn L, Alvarez-Sola G, Latasa MU, Uriarte I, Herranz JM, Arechederra M, et al. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. J Exp Clin Cancer Res. 2022;41:183.","journal-title":"J Exp Clin Cancer Res"},{"key":"2843_CR56","doi-asserted-by":"publisher","first-page":"e174220","DOI":"10.1172\/jci.insight.174220","volume":"9","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Zhang D, Shukla P, Jung Y-H, Malgulwar PB, Chagani S, et al. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight. 2024;9:e174220.","journal-title":"JCI Insight"},{"key":"2843_CR57","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.neo.2019.03.002","volume":"21","author":"L Xu","year":"2019","unstructured":"Xu L, Wang L, Zhou L, Dorfman RG, Pan Y, Tang D, et al. The SIRT2\/cMYC pathway inhibits peroxidation-related apoptosis in cholangiocarcinoma through metabolic reprogramming. Neoplasia. 2019;21:429\u201341.","journal-title":"Neoplasia"},{"key":"2843_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01950-y","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, Wang Y, Wang T, Shi K, Fan S, Li C, et al. CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma. Mol Cancer. 2024;23:35.","journal-title":"Mol Cancer"},{"key":"2843_CR59","doi-asserted-by":"publisher","first-page":"113404","DOI":"10.1016\/j.yexcr.2022.113404","volume":"421","author":"K Fan","year":"2022","unstructured":"Fan K, Zhu K, Wang J, Ni X, Shen S, Gong Z, et al. Inhibition of 14-3-3\u03b5 by K50 acetylation activates YAP1 to promote cholangiocarcinoma growth. Exp Cell Res. 2022;421:113404.","journal-title":"Exp Cell Res"},{"key":"2843_CR60","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1517\/13543784.15.7.815","volume":"15","author":"L Feun","year":"2006","unstructured":"Feun L, Savaraj N. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs. 2006;15:815\u201322.","journal-title":"Expert Opin Investig Drugs"},{"key":"2843_CR61","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","volume":"16","author":"L Satriano","year":"2019","unstructured":"Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16:748\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2843_CR62","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2174\/138161208784246199","volume":"14","author":"L Feun","year":"2008","unstructured":"Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des. 2008;14:1049\u201357.","journal-title":"Curr Pharm Des"},{"key":"2843_CR63","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/ijms22031268","volume":"22","author":"P Balakrishna","year":"2021","unstructured":"Balakrishna P, George S, Hatoum H, Mukherjee S. Serotonin pathway in cancer. Int J Mol Sci. 2021;22:1268.","journal-title":"Int J Mol Sci"},{"key":"2843_CR64","doi-asserted-by":"publisher","first-page":"e12961","DOI":"10.1111\/cpr.12961","volume":"54","author":"S Gu","year":"2021","unstructured":"Gu S, He W, Yan M, He J, Zhou Q, Yan X, et al. Higher content of microcystin-leucine-arginine promotes the survival of intrahepatic cholangiocarcinoma cells via regulating SET resulting in the poorer prognosis of patients. Cell Prolif. 2021;54:e12961.","journal-title":"Cell Prolif"},{"key":"2843_CR65","doi-asserted-by":"publisher","first-page":"e30104","DOI":"10.1016\/j.heliyon.2024.e30104","volume":"10","author":"S Kongsintaweesuk","year":"2024","unstructured":"Kongsintaweesuk S, Klungsaeng S, Intuyod K, Techasen A, Pairojkul C, Luvira V, et al. Microcystin-leucine arginine induces the proliferation of cholangiocytes and cholangiocarcinoma cells through the activation of the Wnt\/\u03b2-catenin signaling pathway. Heliyon. 2024;10:e30104.","journal-title":"Heliyon"},{"key":"2843_CR66","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1158\/0008-5472.CAN-08-2133","volume":"68","author":"G Alpini","year":"2008","unstructured":"Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 2008;68:9184\u201393.","journal-title":"Cancer Res"},{"key":"2843_CR67","doi-asserted-by":"publisher","first-page":"1983.e1","DOI":"10.1053\/j.gastro.2008.08.008","volume":"135","author":"A Villanueva","year":"2008","unstructured":"Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1983.e1\u201311. 1972\u201383.","journal-title":"Gastroenterology"},{"key":"2843_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hep.31310","volume":"73","author":"X Lu","year":"2021","unstructured":"Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the mTOR pathway in liver cancer: from molecular genetics to targeted therapies. Hepatology. 2021;73:49\u201361.","journal-title":"Hepatology"},{"key":"2843_CR69","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cmet.2012.03.015","volume":"15","author":"A Hagiwara","year":"2012","unstructured":"Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 2012;15:725\u201338.","journal-title":"Cell Metab"},{"key":"2843_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ctrv.2018.11.001","volume":"72","author":"F Corti","year":"2019","unstructured":"Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, et al. Targeting the PI3K\/AKT\/mTOR pathway in biliary tract cancers: a review of current evidences and future perspectives. Cancer Treat Rev. 2019;72:45\u201355.","journal-title":"Cancer Treat Rev"},{"key":"2843_CR71","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","volume":"8","author":"T Porstmann","year":"2008","unstructured":"Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8:224\u201336.","journal-title":"Cell Metab"},{"key":"2843_CR72","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1083\/jcb.201306041","volume":"203","author":"C Betz","year":"2013","unstructured":"Betz C, Hall MN. Where is mTOR and what is it doing there?. J Cell Biol. 2013;203:563\u201374.","journal-title":"J Cell Biol"},{"key":"2843_CR73","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrm3522","volume":"14","author":"JL Jewell","year":"2013","unstructured":"Jewell JL, Russell RC, Guan K-L. Amino acid signalling upstream of mTOR. Nat Rev Mol Cell Biol. 2013;14:133\u20139.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2843_CR74","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2008.11.044","volume":"136","author":"P Nicklin","year":"2009","unstructured":"Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136:521\u201334.","journal-title":"Cell"},{"key":"2843_CR75","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.cmet.2019.01.002","volume":"29","author":"AO Adebayo Michael","year":"2019","unstructured":"Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, et al. Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by \u03b2-catenin mutations. Cell Metab. 2019;29:1135\u201350.e6.","journal-title":"Cell Metab"},{"key":"2843_CR76","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jhep.2017.07.006","volume":"67","author":"S Zhang","year":"2017","unstructured":"Zhang S, Song X, Cao D, Xu Z, Fan B, Che L, et al. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. J Hepatol. 2017;67:1194\u2013203.","journal-title":"J Hepatol"},{"key":"2843_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/srep20484","volume":"6","author":"J Hu","year":"2016","unstructured":"Hu J, Che L, Li L, Pilo MG, Cigliano A, Ribback S, et al. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1\/FASN pathway in mice. Sci Rep. 2016;6:20484.","journal-title":"Sci Rep"},{"key":"2843_CR78","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/hep.30697","volume":"70","author":"Z Xu","year":"2019","unstructured":"Xu Z, Xu M, Liu P, Zhang S, Shang R, Qiao Y, et al. The mTORC2-Akt1 cascade is crucial for c-Myc to promote hepatocarcinogenesis in mice and humans. Hepatology. 2019;70:1600\u201313.","journal-title":"Hepatology"},{"key":"2843_CR79","first-page":"00085","volume":"S2090-1232","author":"J Li","year":"2024","unstructured":"Li J, Zhang D, Wang S, Yu P, Sun J, Zhang Y, et al. Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer. J Adv Res. 2024;S2090-1232:00085\u20137.","journal-title":"J Adv Res"},{"key":"2843_CR80","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/apt.15253","volume":"49","author":"SE Grigg","year":"2019","unstructured":"Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharm Ther. 2019;49:1260\u201373.","journal-title":"Aliment Pharm Ther"},{"key":"2843_CR81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/TP.0000000000000965","volume":"100","author":"EK Geissler","year":"2016","unstructured":"Geissler EK, Schnitzbauer AA, Z\u00fclke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116\u201325.","journal-title":"Transplantation"},{"key":"2843_CR82","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/ijmm.2023.5337","volume":"53","author":"M Xu","year":"2023","unstructured":"Xu M, Cui Y, Wei S, Cong X, Chen Y, Tian S, et al. Emerging nanomaterials targeting macrophage adapted to abnormal metabolism in cancer and atherosclerosis therapy (Review). Int J Mol Med. 2023;53:13.","journal-title":"Int J Mol Med"},{"key":"2843_CR83","doi-asserted-by":"publisher","first-page":"e0165118","DOI":"10.1371\/journal.pone.0165118","volume":"11","author":"I Zhang","year":"2016","unstructured":"Zhang I, Alizadeh D, Liang J, Zhang L, Gao H, Song Y, et al. Characterization of arginase expression in glioma-associated microglia and macrophages. PLoS ONE. 2016;11:e0165118.","journal-title":"PLoS ONE"},{"key":"2843_CR84","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13046-025-03430-7","volume":"44","author":"W Zou","year":"2025","unstructured":"Zou W, Han Z, Wang Z, Liu Q. Targeting glutamine metabolism as a potential target for cancer treatment. J Exp Clin Cancer Res. 2025;44:180.","journal-title":"J Exp Clin Cancer Res"},{"key":"2843_CR85","doi-asserted-by":"publisher","first-page":"8322","DOI":"10.7150\/thno.62378","volume":"11","author":"Z Li","year":"2021","unstructured":"Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11:8322\u201336.","journal-title":"Theranostics"},{"key":"2843_CR86","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41422-018-0057-z","volume":"28","author":"W-F Cai","year":"2018","unstructured":"Cai W-F, Zhang C, Wu Y-Q, Zhuang G, Ye Z, Zhang C-S, et al. Glutaminase GLS1 senses glutamine availability in a non-enzymatic manner triggering mitochondrial fusion. Cell Res. 2018;28:865\u20137.","journal-title":"Cell Res"},{"key":"2843_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato LF, Budhu S, Tchaicha J, Weng C-H, Gigoux M, Cohen IJ, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-kynurenine. Nat Commun. 2020;11:4011.","journal-title":"Nat Commun"},{"key":"2843_CR88","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pmn.2022.09.002","volume":"24","author":"H Li","year":"2023","unstructured":"Li H, Lockwood MB, Schlaeger JM, Liu T, Danciu OC, Doorenbos AZ. Tryptophan and kynurenine pathway metabolites and psychoneurological symptoms among breast cancer survivors. Pain Manag Nurs. 2023;24:52\u20139.","journal-title":"Pain Manag Nurs"},{"key":"2843_CR89","doi-asserted-by":"publisher","first-page":"1524651","DOI":"10.3389\/fonc.2024.1524651","volume":"14","author":"I Kang","year":"2025","unstructured":"Kang I, Theodoropoulos G, Wangpaichitr M. Targeting the kynurenine pathway: another therapeutic opportunity in the metabolic crosstalk between cancer and immune cells. Front Oncol. 2025;14:1524651.","journal-title":"Front Oncol"},{"key":"2843_CR90","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/hep.31196","volume":"72","author":"Y Li","year":"2020","unstructured":"Li Y, Lu L, Tu J, Zhang J, Xiong T, Fan W, et al. Reciprocal regulation between forkhead Box M1\/NF-\u03baB and methionine adenosyltransferase 1\u2009A drives liver cancer. Hepatology. 2020;72:1682\u20131700.","journal-title":"Hepatology"},{"key":"2843_CR91","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13046-024-03036-5","volume":"43","author":"W Ma","year":"2024","unstructured":"Ma W, Zhang J, Chen W, Liu N, Wu T. The histone lysine acetyltransferase KAT2B inhibits cholangiocarcinoma growth: evidence for interaction with SP1 to regulate NF2-YAP signaling. J Exp Clin Cancer Res. 2024;43:117.","journal-title":"J Exp Clin Cancer Res"},{"key":"2843_CR92","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-24-0461","volume":"30","author":"J Furuse","year":"2024","unstructured":"Furuse J, Ikeda M, Ueno M, Furukawa M, Morizane C, Takehara T, et al. A Phase II placebo-controlled study of the effect and safety of nanvuranlat in patients with advanced biliary tract cancers previously treated by systemic chemotherapy. Clin Cancer Res. 2024;30:3990\u20135.","journal-title":"Clin Cancer Res"},{"key":"2843_CR93","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1021\/acs.biochem.0c00354","volume":"59","author":"A Radadiya","year":"2020","unstructured":"Radadiya A, Zhu W, Coricello A, Alcaro S, Richards NGJ. Improving the treatment of acute lymphoblastic leukemia. Biochemistry. 2020;59:3193\u2013200.","journal-title":"Biochemistry"},{"key":"2843_CR94","doi-asserted-by":"publisher","first-page":"e20191779","DOI":"10.1084\/jem.20191779","volume":"217","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Lin M, Feng X, Ma F, Zhu Y, Liu X, et al. Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism. J Exp Med. 2020;217:e20191779.","journal-title":"J Exp Med"},{"key":"2843_CR95","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-023-01569-3","volume":"8","author":"Z-N Ling","year":"2023","unstructured":"Ling Z-N, Jiang Y-F, Ru J-N, Lu J-H, Ding B, Wu J. Amino acid metabolism in health and disease. Signal Transduct Target Ther. 2023;8:345.","journal-title":"Signal Transduct Target Ther"},{"key":"2843_CR96","doi-asserted-by":"publisher","first-page":"216493","DOI":"10.1016\/j.canlet.2023.216493","volume":"580","author":"K Nagaoka","year":"2024","unstructured":"Nagaoka K, Bai X, Liu D, Cao K, Mulla J, Ji C, et al. Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase. Cancer Lett. 2024;580:216493.","journal-title":"Cancer Lett"},{"key":"2843_CR97","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.21037\/jgo-23-115","volume":"14","author":"C Fountzilas","year":"2023","unstructured":"Fountzilas C, Velasco SA, Bshara W, LeVea CM, Gupta M, Ji W, et al. Evaluation of the serotonin pathway as a biomarker in cholangiocarcinoma. J Gastrointest Oncol. 2023;14:2192\u2013201.","journal-title":"J Gastrointest Oncol"},{"key":"2843_CR98","doi-asserted-by":"publisher","first-page":"e18585","DOI":"10.1111\/jcmm.18585","volume":"28","author":"N Awasthi","year":"2024","unstructured":"Awasthi N, Darman L, Schwarz MA, Schwarz RE. Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models. J Cell Mol Med. 2024;28:e18585.","journal-title":"J Cell Mol Med"},{"key":"2843_CR99","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40170-021-00249-6","volume":"9","author":"M Thanee","year":"2021","unstructured":"Thanee M, Padthaisong S, Suksawat M, Dokduang H, Phetcharaburanin J, Klanrit P, et al. Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models. Cancer Metab. 2021;9:11.","journal-title":"Cancer Metab"},{"key":"2843_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66945-7","volume":"14","author":"P Thongpon","year":"2024","unstructured":"Thongpon P, Intuyod K, Chomwong S, Pongking T, Klungsaeng S, Muisuk K, et al. Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2\/glutamine pathway. Sci Rep. 2024;14:16059.","journal-title":"Sci Rep"},{"key":"2843_CR101","doi-asserted-by":"publisher","first-page":"9226","DOI":"10.3390\/ijms25179226","volume":"25","author":"X Wu","year":"2024","unstructured":"Wu X, Li Y, Han C, Li S, Qin X. Discovery of aloperine as a potential antineoplastic agent for cholangiocarcinoma harboring mutant IDH1. Int J Mol Sci. 2024;25:9226.","journal-title":"Int J Mol Sci"},{"key":"2843_CR102","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1007\/s00262-023-03534-z","volume":"72","author":"M Wahid","year":"2023","unstructured":"Wahid M, Pratoomthai B, Egbuniwe IU, Evans HR, Babaei-Jadidi R, Amartey JO, et al. Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion. Cancer Immunol Immunother. 2023;72:4001\u201314.","journal-title":"Cancer Immunol Immunother"},{"key":"2843_CR103","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/JCO.2021.39.3_suppl.311","volume":"39","author":"MM Javle","year":"2021","unstructured":"Javle MM, Bridgewater JA, Gbolahan OB, Jungels C, Cho MT, Papadopoulos KP, et al. A phase I\/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers. J Clin Oncol. 2021;39:311\u2013311.","journal-title":"J Clin Oncol"},{"key":"2843_CR104","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/hep.31466","volume":"73","author":"D Ostroumov","year":"2021","unstructured":"Ostroumov D, Duong S, Wingerath J, Woller N, Manns MP, Timrott K, et al. Transcriptome profiling identifies TIGIT as a marker of T-cell exhaustion in liver cancer. Hepatology. 2021;73:1399\u2013418.","journal-title":"Hepatology"},{"key":"2843_CR105","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22:259\u201367.","journal-title":"Clin Cancer Res"},{"key":"2843_CR106","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/cancers15071970","volume":"15","author":"MM Queiroz","year":"2023","unstructured":"Queiroz MM, Lima NF, Biachi, de Castria T. Immunotherapy and targeted therapy for advanced biliary tract cancer: adding new flavors to the pizza. Cancers. 2023;15:1970.","journal-title":"Cancers"},{"key":"2843_CR107","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"2843_CR108","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/HEP.0000000000000552","volume":"79","author":"L Zhao","year":"2024","unstructured":"Zhao L, Liu J, Li K, Zhang C, Chen T, Liu Z, et al. PTPN9 dephosphorylates FGFR2 pY656\/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma. Hepatology. 2024;79:798\u2013812.","journal-title":"Hepatology"},{"key":"2843_CR109","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jhep.2022.09.014","volume":"78","author":"CB Conboy","year":"2023","unstructured":"Conboy CB, Yonkus JA, Buckarma EH, Mun D-G, Werneburg NW, Watkins RD, et al. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma. J Hepatol. 2023;78:142\u201352.","journal-title":"J Hepatol"},{"key":"2843_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45247-6","volume":"15","author":"S Spahn","year":"2024","unstructured":"Spahn S, Kleinhenz F, Shevchenko E, Stahl A, Rasen Y, Geisler C, et al. The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma. Nat Commun. 2024;15:1287.","journal-title":"Nat Commun"},{"key":"2843_CR111","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491\u2013505.","journal-title":"Ann Oncol"},{"key":"2843_CR112","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21:1234\u201343.","journal-title":"Lancet Oncol."},{"key":"2843_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36399-y","volume":"14","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Piha-Paul SA, Shah RH, Murphy JJ, Cleary JM, Shapiro GI, et al. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nat Commun. 2023;14:630.","journal-title":"Nat Commun"},{"key":"2843_CR114","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","volume":"15","author":"B Wilding","year":"2025","unstructured":"Wilding B, Woelflingseder L, Baum A, Chylinski K, Vainorius G, Gibson N, et al. Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. Cancer Discov. 2025;15:119\u201338.","journal-title":"Cancer Discov"},{"key":"2843_CR115","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2017.11.024","volume":"90","author":"J Delahousse","year":"2018","unstructured":"Delahousse J, Verlingue L, Broutin S, Legoupil C, Touat M, Doucet L, et al. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. Eur J Cancer. 2018;90:83\u201391.","journal-title":"Eur J Cancer"},{"key":"2843_CR116","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796\u2013807.","journal-title":"Lancet Oncol"},{"key":"2843_CR117","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7:1669\u201377.","journal-title":"JAMA Oncol"},{"key":"2843_CR118","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41422-022-00650-w","volume":"32","author":"X Wang","year":"2022","unstructured":"Wang X, Chen Z, Xu J, Tang S, An N, Jiang L, et al. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Res. 2022;32:638\u201358.","journal-title":"Cell Res"},{"key":"2843_CR119","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","volume":"6","author":"SK Saha","year":"2016","unstructured":"Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016;6:727\u201339.","journal-title":"Cancer Discov."},{"key":"2843_CR120","doi-asserted-by":"publisher","first-page":"eadj7685","DOI":"10.1126\/scitranslmed.adj7685","volume":"16","author":"IS Luk","year":"2024","unstructured":"Luk IS, Bridgwater CM, Yu A, Boila LD, Y\u00e1\u00f1ez-Bartolom\u00e9 M, Lampano AE, et al. SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma. Sci Transl Med. 2024;16:eadj7685.","journal-title":"Sci Transl Med"},{"key":"2843_CR121","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/intimm\/dxaa019","volume":"32","author":"M Miyajima","year":"2020","unstructured":"Miyajima M. Amino acids: key sources for immunometabolites and immunotransmitters. Int Immunol. 2020;32:435\u201346.","journal-title":"Int Immunol"},{"key":"2843_CR122","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-023-01453-1","volume":"16","author":"L Yang","year":"2023","unstructured":"Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q, et al. Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy. J Hematol Oncol. 2023;16:59.","journal-title":"J Hematol Oncol"},{"key":"2843_CR123","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","volume":"12","author":"MJ Wu","year":"2022","unstructured":"Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, et al. Mutant IDH inhibits IFN\u03b3-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov. 2022;12:812\u201335.","journal-title":"Cancer Discov"},{"key":"2843_CR124","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-17-3855","volume":"24","author":"L Zhang","year":"2018","unstructured":"Zhang L, Sorensen MD, Kristensen BW, Reifenberger G, McIntyre TM, Lin F. D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas inhibiting complement and T cells. Clin Cancer Res. 2018;24:5381\u201391.","journal-title":"Clin Cancer Res"},{"key":"2843_CR125","doi-asserted-by":"publisher","unstructured":"Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, et al. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2\/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004644.","DOI":"10.1136\/jitc-2022-004644"},{"key":"2843_CR126","doi-asserted-by":"publisher","first-page":"e2309203","DOI":"10.1002\/advs.202309203","volume":"11","author":"Q Zheng","year":"2024","unstructured":"Zheng Q, Zou T, Wang W, Zhang C, Hu S, Cheng X, et al. Necroptosis-mediated synergistic photodynamic and glutamine-metabolic therapy enabled by a biomimetic targeting nanosystem for cholangiocarcinoma. Adv Sci. 2024;11:e2309203.","journal-title":"Adv Sci"},{"key":"2843_CR127","doi-asserted-by":"publisher","first-page":"e2307143","DOI":"10.1002\/advs.202307143","volume":"11","author":"W Wang","year":"2024","unstructured":"Wang W, Gao Y, Xu J, Zou T, Yang B, Hu S, et al. A NRF2 regulated and the immunosuppressive microenvironment reversed nanoplatform for cholangiocarcinoma photodynamic-gas therapy. Adv Sci. 2024;11:e2307143.","journal-title":"Adv Sci"},{"key":"2843_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02569-3","volume":"22","author":"S Hua","year":"2024","unstructured":"Hua S, Dong X, Peng Q, Zhang K, Zhang X, Yang J. Single-atom nanozymes shines diagnostics of gastrointestinal diseases. J Nanobiotechnol. 2024;22:286.","journal-title":"J Nanobiotechnol"},{"key":"2843_CR129","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.jhepr.2023.100762","volume":"5","author":"C Zhu","year":"2023","unstructured":"Zhu C, Ma J, Zhu K, Yu L, Zheng B, Rao D, et al. Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma. JHEP Rep. 2023;5:100762.","journal-title":"JHEP Rep."},{"key":"2843_CR130","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000530700","volume":"13","author":"L Ye","year":"2024","unstructured":"Ye L, Schneider JS, Ben Khaled N, Schirmacher P, Seifert C, Frey L, et al. Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management. Liver Cancer. 2024;13:6\u201328.","journal-title":"Liver Cancer"},{"key":"2843_CR131","doi-asserted-by":"publisher","first-page":"101657","DOI":"10.1016\/j.redox.2020.101657","volume":"36","author":"S Jalali","year":"2020","unstructured":"Jalali S, Shi J, Buko A, Ahsan N, Paludo J, Serres M, et al. Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia. Redox Biol. 2020;36:101657","journal-title":"Redox Biol"},{"key":"2843_CR132","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.3390\/cancers15205082","volume":"15","author":"XD Lyu","year":"2023","unstructured":"Lyu XD, Liu Y, Wang J, Wei Y-C, Han Y, Li X, et al. A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer. Cancers (Basel). 2023;15:5082","journal-title":"Cancers (Basel)"},{"key":"2843_CR133","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cmet.2013.11.022","volume":"19","author":"RC Sun","year":"2014","unstructured":"Sun RC, Denko NC. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 2014;19:285\u201392.","journal-title":"Cell Metab"},{"key":"2843_CR134","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","volume":"3","author":"RA Cairns","year":"2013","unstructured":"Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3:730\u201341.","journal-title":"Cancer Discov"},{"key":"2843_CR135","doi-asserted-by":"publisher","first-page":"e99945","DOI":"10.15252\/embj.201899945","volume":"38","author":"B Yuan","year":"2019","unstructured":"Yuan B, Liu J, Cao J, Yu Y, Zhang H, Wang F, et al. PTPN3 acts as a tumor suppressor and boosts TGF-\u03b2 signaling independent of its phosphatase activity. EMBO J. 2019;38:e99945","journal-title":"EMBO J"},{"key":"2843_CR136","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.omtn.2021.01.001","volume":"23","author":"R Yuan","year":"2021","unstructured":"Yuan R, Li Y, Yang B, Jin Z, Xu J, Shao Z, et al. LOXL1 exerts oncogenesis and stimulates angiogenesis through the LOXL1- FBLN5\/\u03b1v\u03b23 integrin\/FAK-MAPK axis in ICC. Mol Ther Nucleic Acids. 2021;23:797\u2013810.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2843_CR137","doi-asserted-by":"publisher","first-page":"113316","DOI":"10.1016\/j.intimp.2024.113316","volume":"143","author":"J Fan","year":"2024","unstructured":"Fan J, Wang X, Wang Y, Song J, Chen M, Weng C, et al. Dietary glutamine supplementation improves both Th1 and Th17 responses via CARD11-mTORC1 pathway in murine model of atopic dermatitis. Int Immunopharmacol. 2024;143:113316","journal-title":"Int Immunopharmacol"},{"key":"2843_CR138","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","volume":"81","author":"C Kang","year":"2021","unstructured":"Kang C. Infigratinib: First Approval. Drugs. 2021;81:1355\u201360.","journal-title":"Drugs"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02843-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02843-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:03:27Z","timestamp":1782925407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02843-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":138,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02843-9","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The currently published name does not accurately reflect the official designation of our institution. I would like to emphasize that this change involves only the habitual English translation of the first affiliation\u2019s name, without altering the affiliation itself, the order of authors, or any other content of the article.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}